dihexa retracted paper controversy Good news! 📰⁠ ⁠ Takeda announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy Retraction | The Transmitter: Neuroscience

We showed that cirrhotic (an IGF-1 deficiency condition) rats had diminished amino acid and glucose intestinal absorption [114, 194, 195] and that IGF-1 replacement therapy was able to restore both alterations, suggesting a role of IGF-1 in the position of transporters [196]

May your reconstitution stay precise, your concentrations stay accurate, and your results stay consistent.

Heal & Protect Your Gut Repairs the stomach lining, reduces leaky gut, and calms GI inflammation, making BPC-157 uniquely effective for digestive issues alongside physical recovery

[8] [9] This means that higher oral doses may be required in certain circumstances to achieve therapeutic effects

The concern isnt just that youll develop antibodies against the peptide itselfits that those antibodies might cross-react with your own endogenous proteins